piracetam has been researched along with Innate Inflammatory Response in 11 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was performed to investigate the effect of piracetam on neuroinflammation induced by lipopolysaccharide (LPS) and resulting changes in cognitive behavior." | 7.85 | Piracetam Attenuates LPS-Induced Neuroinflammation and Cognitive Impairment in Rats. ( Krishnamurthy, S; Paliwal, P; Tripathi, A, 2017) |
| "Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan." | 7.78 | The local peripheral antihyperalgesic effect of levetiracetam and its mechanism of action in an inflammatory pain model. ( Micov, AM; Stepanović-Petrović, RM; Tomić, MA; Ugrešić, ND, 2012) |
| "The effect of piracetam has been studied in experimental models of the inflammatory process--the models of rat's paw oedema and intraperitoneal formalin ascites for the exudative phase and the cotton pellet model for the proliferative phase." | 7.67 | Effect of piracetam in models of experimental inflammation. ( Dushkova, R; Nikolova, M; Petrova, L, 1984) |
| " The pharmacokinetic profiles of R-PhP in mouse plasma and its bioavailability in brain tissue were assessed." | 5.56 | Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. ( Dambrova, M; Grinberga, S; Stelfa, G; Svalbe, B; Vavers, E; Videja, M; Zvejniece, B; Zvejniece, L, 2020) |
| "Levetiracetam (LEV) suppresses the upregulation of proinflammatory molecules that occurs during epileptogenesis after status epilepticus (SE)." | 4.12 | Regulation of Inflammation-Related Genes through ( Hashimoto, R; Ishihara, Y; Itoh, K; Komori, R; Kono, T; Kozawa, C; Kubo, S; Matsuo, T; Yokota-Nakatsuma, A, 2022) |
| "The present study was performed to investigate the effect of piracetam on neuroinflammation induced by lipopolysaccharide (LPS) and resulting changes in cognitive behavior." | 3.85 | Piracetam Attenuates LPS-Induced Neuroinflammation and Cognitive Impairment in Rats. ( Krishnamurthy, S; Paliwal, P; Tripathi, A, 2017) |
| " These results suggest that ceftriaxone, particularly in combinations with ibuprofen, celecoxib, paracetamol, or levetiracetam, may provide useful approach to the clinical treatment of inflammation-related pain." | 3.80 | Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents. ( Boškovic, BD; Kovacevic, JM; Micov, AM; Stepanovic-Petrovic, RM; Tomic, MA, 2014) |
| " This study characterized the manner in which levetiracetam interacts with analgesics (ibuprofen, celecoxib, and paracetamol) and caffeine to suppress hyperalgesia in a model of localized inflammation." | 3.79 | Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats. ( Micov, AM; Stepanović-Petrović, RM; Tomić, MA, 2013) |
| "Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan." | 3.78 | The local peripheral antihyperalgesic effect of levetiracetam and its mechanism of action in an inflammatory pain model. ( Micov, AM; Stepanović-Petrović, RM; Tomić, MA; Ugrešić, ND, 2012) |
| "The effect of piracetam has been studied in experimental models of the inflammatory process--the models of rat's paw oedema and intraperitoneal formalin ascites for the exudative phase and the cotton pellet model for the proliferative phase." | 3.67 | Effect of piracetam in models of experimental inflammation. ( Dushkova, R; Nikolova, M; Petrova, L, 1984) |
| " The pharmacokinetic profiles of R-PhP in mouse plasma and its bioavailability in brain tissue were assessed." | 1.56 | Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. ( Dambrova, M; Grinberga, S; Stelfa, G; Svalbe, B; Vavers, E; Videja, M; Zvejniece, B; Zvejniece, L, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Komori, R | 1 |
| Matsuo, T | 1 |
| Yokota-Nakatsuma, A | 1 |
| Hashimoto, R | 1 |
| Kubo, S | 1 |
| Kozawa, C | 1 |
| Kono, T | 1 |
| Ishihara, Y | 1 |
| Itoh, K | 1 |
| Zvejniece, L | 1 |
| Zvejniece, B | 1 |
| Videja, M | 1 |
| Stelfa, G | 1 |
| Vavers, E | 1 |
| Grinberga, S | 1 |
| Svalbe, B | 1 |
| Dambrova, M | 1 |
| Block, L | 1 |
| Björklund, U | 1 |
| Westerlund, A | 1 |
| Jörneberg, P | 1 |
| Biber, B | 1 |
| Hansson, E | 1 |
| Tomić, MA | 3 |
| Micov, AM | 3 |
| Stepanović-Petrović, RM | 3 |
| Kovacevic, JM | 1 |
| Boškovic, BD | 1 |
| Tyurenkov, IN | 1 |
| Samotrueva, MA | 1 |
| Tsibizova, AA | 1 |
| Yasenyavskaya, AL | 1 |
| Tripathi, A | 1 |
| Paliwal, P | 1 |
| Krishnamurthy, S | 1 |
| Ugrešić, ND | 1 |
| Marini, H | 1 |
| Costa, C | 1 |
| Passaniti, M | 1 |
| Esposito, M | 1 |
| Campo, GM | 1 |
| Ientile, R | 1 |
| Adamo, EB | 1 |
| Marini, R | 1 |
| Calabresi, P | 1 |
| Altavilla, D | 1 |
| Minutoli, L | 1 |
| Pisani, F | 1 |
| Squadrito, F | 1 |
| Nikolova, M | 1 |
| Petrova, L | 1 |
| Dushkova, R | 1 |
11 other studies available for piracetam and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Regulation of Inflammation-Related Genes through
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Inflammation; Levetiracetam; Mice; Piloc | 2022 |
Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice.
Topics: Animals; Anti-Inflammatory Agents; Biological Availability; Brain; Disease Models, Animal; Dopamine | 2020 |
A new concept affecting restoration of inflammation-reactive astrocytes.
Topics: Actins; Analgesics, Opioid; Animals; Astrocytes; Calcium Signaling; Capillaries; Coculture Technique | 2013 |
Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Celecoxib; Dr | 2013 |
Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Ce | 2014 |
[PHENOTROPIL AS MODULATOR OF CYTOKINE LEVEL UNDER CONDITIONS OF EXPERIMENTAL IMMUNOPATHOLOGY].
Topics: Animals; Cyclophosphamide; Drug Administration Schedule; Immunity, Innate; Immunologic Factors; Immu | 2015 |
Piracetam Attenuates LPS-Induced Neuroinflammation and Cognitive Impairment in Rats.
Topics: Animals; Cognitive Dysfunction; Dose-Response Relationship, Drug; Inflammation; Inflammation Mediato | 2017 |
The local peripheral antihyperalgesic effect of levetiracetam and its mechanism of action in an inflammatory pain model.
Topics: Adenosine A1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anesthetics, Local; Animals; Carrag | 2012 |
Levetiracetam protects against kainic acid-induced toxicity.
Topics: Animals; Behavior, Animal; Brain; Cells, Cultured; Cerebral Cortex; Diencephalon; DNA Primers; Excit | 2004 |
Effect of piracetam in models of experimental inflammation.
Topics: Animals; Anti-Inflammatory Agents; Ascites; Cell Membrane Permeability; Dose-Response Relationship, | 1984 |